>Revista de Hematología
>Year 2016, Issue 1
Sánchez-López JM, Alcaraz-Rubio J, Oliver-Iguace A
Platelet-derived leukocyte growth factors in cerebral palsy
Rev Hematol Mex 2016; 17 (1)
PDF: 984.47 Kb.
Background: Platelet-rich plasma is now a common medical technique
known as regenerative medicine, through power cell activation
and differentiation, which produces different growth factors, depending
on the cell fraction recovered in the final product both locally and
Objective: To report the benefit of the systemic application of plasma
growth factors in patients with cerebral palsy undergoing specific programs
Material and Method:: A case-control study done in a population
of 50 Caucasian patients under the same program of neurorehabilitation
and age range between 5 and 15 years with perinatal cerebral palsy,
cognitive impairment, and marked and severe generalized spasticity;
we administered an intravenous injection of concentrated leukocyterich
plasma (25 cc) in a group of 25 of them. We performed follow-up
at 1, 2, 3, 4, 5 and 6 months after the injection. All serum samples
for determination were obtained by ELISA technique and Beckman
Coulter. Cognitive Barthel scale was used before and after treatment.
The determination protocol that was applied before the analysis was
performed manually and the self-transfusion was considered suitable for
treatment. We determined cellular composition and the plasma levels
of factor similar to insulin-1 (IGF-1), platelet-derived growth factor
(PDGF), vasculo-endothelial growth factor (VEGF), and transforming
growth factor β (TGF-β) before, in the final product obtained in both
groups before treatment and at 24 hours and at 1, 2, 3, 4, 5 and 6 months
after treatment. Correlations between Cognitive responses in the two
population groups throughout the follow-up period were analyzed by
Fisher correlation analysis.
Results: No adverse effects were observed in the patients except for a
small hematoma in the area channeling venous access. We observed a
clear improvement in the cognitive sphere (memory, ability to perform
more complex tasks, and acquisition of new skills) clearly higher in the
group of patients treated with plasma rich in leukocyte growth factors,
significantly statistical difference at 2 months follow-up (p=0.013),
maintaining stable from the third month follow-up. Although after 24
hours of treatment in the group of treatment, serum levels of growth
factors type VEGF and TGF-β increased 5-6 fold over baseline levels
and the group control (p=0.02), it was not correlated with cognitive
improvement over six months of clinical follow-up in this group, since
virtually objectified plasma levels of growth factors were similar in both
groups from the month follow-up study.
Conclusions: We propose that this therapy is useful in these patients
to harness the neurostimulative and neuroregenerative power of endogenous
growth factors derived from leukocytes, enhancing the effect of
neurorehabilitation and shortening cognitive recovery
||leukocyte-rich plasma, cerebral palsy, growth factors, neuronal plasticity, intravenous infusion.
Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Aurologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:415.
Lorente A, Ortega R, Martín M, López J, Martínez JM. Quantification of growth factors by using a new system for obtaining platelet-rich plasma. Med Oral Patol Oral Cir Bucal 2011;614-618.
Weibrich G, Kleis W, Hafner G. Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type kit versus PCCS PRP system. Int J Oral Maxillofac Implats 2002;17:184-190.
Weibrich G, Kleis W, Hafner G. Growth factor levels in platelet-rich plasma and correlations with donor age, sex and platelet count. J Craniomaxillofac Surg 2002;30:97-102.
Harguindey S. Apoptosis y antiapoptosis en cáncer. Alzheimer y procesos neurodegenerativos: ¿una dialéctica de contrarios? Nuevo abanico de posibilidades terapéuticas y peligros potenciales. Oncología 2004;27:579-589.
Brea D, Sobrino T, Ramos P, Castillo J. Reorganización de la vascularización cerebral tras la isquemia. Rev Neurol 2009;49:645-654.
Legido A, Valencia I, Katsetos C, Papadopoulos M. Neuroprotección en la encefalopatía hipóxico isquémica perinatal. Tratamientos con eficacia clínica demostrada y perspectivas futuras. Medicina (Buenos Aires) 2007;67(6/1):543-555.
Devesa J, Alonso B, Casteleiro N, Couto P, et al. Effects of recombinant growth hormone (GH) replacement and psychomotor and cognitive stimulation in the neurodevelopment of GH-deficient (GHD) children with cerebral palsy: a pilot study. Ther Clin Risk Manag 2011;7:199-206.
Taudorf K, Hansen FJ, Mechior JC, Pedersen H. Spontaneous remission of cerebral palsy. Neuropediatrics 1986;17:19-22.
Alcaraz J, Oliver A, Sánchez JM. Platelet rich plasma in a patient with cerebral palsy. Am J Case Rep 2015;16:1-4.
Alcaraz, J, Oliver, A, Sánchez JM. Nuevo método de obtención de plasma rico en factores de crecimiento plaquetario (PRP). Estudio descriptivo en 15 pacientes y comparación con los resultados publicados en la bibliografía. Rev Hematol Mex 2015;16:210-216.
Alcaraz J, Oliver A, Sánchez JM, Lajara J. Clinical use of platelet-rich plasma: A new dimension in Regenerative Medicine. Med Sci Rev 2015;2:111-120.
>Revista de Hematología
>Year 2016, Issue 1